A practical reference on fatty diacid: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The study also highlights economy-specific gap analyses, which illustrate gaps in policy coverage and estimate potential energy savings achieved through the adoption of world’s most comprehensive standards. Compliance Counts: A Practitioners Guidebook on Best Practice Monitoring, Verification, and Enforcement (MV&E) for Appliance Standards &Labeling The Guidebook, published in collaboration with Mark Ellis & Associates, is designed as a step-by-step manual for policymakers and S&L program administrators to design and implement a successful compliance regime. Drawing on the experiences of existing S&L programs worldwide, the Guidebook provides different approaches to implementing and improving all aspects of a compliance framework, including establishment of a legal basis for MV&E activities and enforcement options for non-compliance. According to the guidebook, effective compliance regimes: ensure that consumers receive the products they expect when making purchasing decisions; provide industry participants a fair market in which to operate; and safeguard current and future energy and greenhouse gas emissions savings from S&L programs, among other benefits. Energy Efficiency Labels and Standards: A Guidebook for Appliances, Equipment, And Lighting (also available in Chinese, Spanish and Korean) This guidebook is designed as a manual for government officials and others around the world responsible for developing, implementing, enforcing, monitoring, and maintaining energy efficiency labeling and standard-setting programs. Tools
=== Molded graphene === In 2015, researchers from the University of Illinois at Urbana–Champaign (UIUC) developed a new approach for forming 3D shapes from flat, 2D sheets of graphene. A film of graphene that had been soaked in solvent to make it swell and become malleable was overlaid on an underlying substrate "former". The solvent evaporated over time, leaving behind a layer of graphene that had taken on the shape of the underlying structure. In this way, they were able to produce a range of relatively intricate micro-structured shapes. Features vary from 3.5 to 50 μm. Pure graphene and gold-decorated graphene were each successfully integrated with the substrate.
The 100K Wellness Project was a 10-month Framingham-style longitudinal study, organized by Leroy Hood. The pilot phase took place between March and December 2014. Participants submitted integrated data from whole-genome sequencing, gut microbiome, clinical laboratory tests and quantified self measures to provide actionable results for health coaching. It showed actionable opportunities in all participants, and participants followed actionable guidelines about 70 percent of the time. It later would transition into the wellness startup Arivale.
Sources: en.wikipedia.org
The notochord is the defining feature (synapomorphy) of chordates, and was present throughout life in many of the earliest chordates. Although the stomochord of hemichordates was once thought to be homologous or from a common lineal origin, it is now viewed as analogous, convergent, or from a different lineal origin. Pikaia appears to have a proto-notochord, and notochords are present in several basal chordates such as Haikouella, Haikouichthys, and Myllokunmingia, all from the Cambrian. The Ordovician oceans included many diverse species of Agnatha and early Gnathostomata which possessed notochords, either with attached bony elements or without, most notably the conodonts, placoderms, and ostracoderms. Even after the evolution of the vertebral column in chondrichthyes and osteichthyes, these taxa remained common and are well represented in the fossil record. Several species (see list below) have reverted to the primitive state, retaining the notochord into adulthood, though the reasons for this are not well understood. Scenarios for the evolutionary origin of the notochord were comprehensively reviewed by Annona, Holland, and D'Aniello (2015). They point out that, although many of these ideas have not been well supported by advances in molecular phylogenetics and developmental genetics, two of them have actually been revived under the stimulus of modern molecular approaches:
Activities of focus included concentrated weightlifting, change of diet, and the use of creatine and androstenedione. By the start of the 1996 season, Bagwell and Biggio had gained seniority, even if not necessarily by age, within the Astros clubhouse as well as status as superstars. According to sportswriter Dayn Perry, the earliest recorded reference to an Astros version of the nickname "Killer B's" encountered via a Google Search occurred that year. Bagwell enforced accountability and preparation which fostered camaraderie and incorporated all players as instrumental to the success of the team. Thus, the Astros raised their level of play, and a new string of playoff appearances followed. In time, all who entered the Astros gym were greeted with a banner that read: "Bagwell's Gym. Work Hard. Play Hard. Or Leave." On May 7 against Philadelphia, Bagwell reached the 500th RBI of his career with two home runs and four RBI. By hitting his second upper-deck home run at Three Rivers Stadium on May 29 — it travelled 459 feet (140 m) — Bagwell joined longtime Pirate Willie Stargell as the only players to homer twice into the stadium's upper deck. For the month of May, he batted .360 with .740 SLG, 10 home runs, 31 RBI, 22 runs scored, and four stolen bases. He was named NL Player of the Month, his fourth career monthly award. On June 14, Bagwell tied a major league record with four doubles in one game against San Francisco. He played all 162 games that year, batting .315 with a 1.021 OPS, 31 home runs, 120 RBI, 111 runs scored, and 135 walks.
Hezbollah's senior leadership faced the heaviest casualties in its entire history during the conflict. According to the IDF, 13 members of Hezbollah's senior command were killed. Its political council lost figures such as Secretary-General Hassan Nasrallah, who ruled the group for over three decades, and his deputy, Hashem Safieddine. Its armed wing lost key leaders such as Fuad Shukr, Hezbollah's military commander; Ibrahim Aqil, Shukr's deputy; and Ali Karaki, the commander of Hezbollah's Southern Front. Hezbollah also saw heavy damage inflicted upon its equipment, missile arsenal and infrastructure in southern Lebanon, weakening its operational capacity. Heavy damage was inflicted upon military infrastructure such as bases, tunnels, weapon depots, and fortifications, and its arms supply has been disrupted by Israeli strikes on Syrian border crossings. According to IDF, they confiscated over 155,000 weapons and pieces of military equipment belonging to Hezbollah, including around 12,000 explosive devices, drones, and other explosive weapons, more than 13,000 anti-tank missile launchers and rockets, and anti-aircraft missiles. In addition, over 121,000 communication devices, computers, electronic equipment and documents were also captured. In April 2025, in response to increasing calls for its disarmament, Hezbollah expressed willingness to engage in discussions about its weapons with Lebanese President Joseph Aoun. These discussions would be contingent upon Israel's withdrawal from five hilltop positions in southern Lebanon and the cessation of its military strikes.
==== Mongolia ==== After serious opposition about plans and negotiations between Mongolia with Japan and the United States to build nuclear-waste facilities in Mongolia, Mongolia stopped all negotiations in September 2011. These negotiations had started after U.S. Deputy Secretary of Energy Daniel Poneman visited Mongolia in September 2010. Talks took place in Washington, D.C. between officials of Japan, the United States, and Mongolia in February 2011. After this the United Arab Emirates (UAE), which wanted to buy nuclear fuel from Mongolia, joined in the negotiations. The talks were kept secret and, although the Mainichi Daily News reported on them in May, Mongolia officially denied the existence of these negotiations. Alarmed by this news, Mongolian citizens protested against the plans and demanded the government withdraw the plans and disclose information. The Mongolian President Tsakhiagiin Elbegdorj issued a presidential order on September 13 banning all negotiations with foreign governments or international organizations on nuclear-waste storage plans in Mongolia. The Mongolian government has accused the newspaper of distributing false claims around the world. After the presidential order, the Mongolian president fired the individual who was supposedly involved in these conversations.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.